What are the ways to go to support domestically-made innovative drugs?

At present, my country's pharmaceutical industry is entering a critical stage of comprehensive transformation and upgrading.

Under the guidance of the implementation of the "Healthy China" strategy proposed by the 19th National Congress of the Communist Party of China, my country's implementation of the "New Drug Creation" major project has achieved fruitful results in the research and development of innovative drugs.

At the two sessions this year, many representatives of the pharmaceutical industry offered advice and suggestions for my country's pharmaceutical innovation.

He pointed out that how to improve and optimize the ecological environment of domestically produced innovative drugs and how to enhance the enthusiasm of local pharmaceutical companies for independent innovation will affect the development of my country's pharmaceutical industry in the next ten years.

As a representative of the early domestic innovative drugs, the once-hot-selling antihypertensive compound reserpine and triamterene tablets (formerly known as Beijing Jiangya No.

Hypertension is a chronic disease with a long history, widespread prevalence, and major harm to human health.

In the early 1970s, Dr.

No.

In 1970, academician Wu Yingkai, a well-known medical scientist in China, one of the founders of Chinese Cardiac Surgery, and the president of the Chinese Academy of Medical Sciences, was also deeply troubled by the prevention and treatment of hypertension.

After more than 40 years of clinical practice, the antihypertensive drug No.

And in the community, with the same antihypertensive effect, the price of No.

According to data from Menet.

Based on the early development of domestically-made innovative drugs, and the actual situation of the current stage of my country's pharmaceutical innovation and development.

In terms of supporting domestically-made innovative drugs, Ding Xiaobing pointed out that it is necessary to accelerate the establishment of an enterprise-based integrated innovation mechanism of production, education and research, establish a close cooperation model of “enterprise-university-scientific research institutions”, optimize the allocation of resources for the pharmaceutical innovation industry, and continuously improve domestic pharmaceuticals.

At the same time, speed up the inclusion of innovative therapeutic drugs in the medical insurance catalog, prioritize innovative drugs into the national medical insurance catalog, further standardize the update and adjustment cycle of the medical insurance drug catalog, improve the scientific evaluation mechanism for the selection of the medical insurance drug catalog, deepen the reform of the examination and approval system, and give priority to the review of innovative drugs , Reform the management model of drug clinical trials, and conditionally approve innovative drugs.